NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

104.94 -3.91 (-3.59%)
As of 12:25 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Stephane Bancel CEO & Director 4.55M 300.71M 1973
Dr. Stephen Hoge M.D. President 1.92M -- 1977
Mr. James M. Mock Chief Financial Officer 1.4M -- 1977
Ms. Shannon Thyme Klinger Chief Legal Officer & Corporate Secretary 1.39M -- 1971
Dr. Jerh Collins Ph.D. Chief Technical Operations & Quality Officer -- -- 1967
Mr. Brad Miller Chief Information Officer -- -- 1974
Ms. Lavina Talukdar CFA Senior VP & Head of Investor Relations -- -- --
Colleen Hussey Senior Director of Corporate Communications -- -- --
Ms. Tracey Franklin Chief Human Resources Officer -- -- 1981
Dr. Melanie Ivarsson M.B.A., Ph.D. Chief Development Officer -- -- --

Moderna, Inc.

200 Technology Square
Cambridge, MA 02139
United States
617 714 6500 https://www.modernatx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
5,600

Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Moderna, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 10; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024
Moderna, Inc. Earnings Call

Related Tickers

BNTX BioNTech SE
86.66
-1.63%
 
NVAX Novavax, Inc.
3.9500
-4.81%
 
CRSP CRISPR Therapeutics AG
53.29
-4.24%
 
VKTX Viking Therapeutics, Inc.
67.23
+3.32%
 
VRTX Vertex Pharmaceuticals Incorporated
397.48
-0.82%
 
NVO Novo Nordisk A/S
124.91
-0.99%
 
RXRX Recursion Pharmaceuticals, Inc.
7.63
-3.97%
 
REGN Regeneron Pharmaceuticals, Inc.
891.58
-1.65%
 
NTLA Intellia Therapeutics, Inc.
19.99
-5.57%
 
INO Inovio Pharmaceuticals, Inc.
10.02
-1.39%